NASH therapy from Novartis adds 15th program to Boston Pharmaceuticals’ pipeline

With this week’s addition of a NASH therapy from Novartis, Boston Pharmaceuticals is well on its way to the goal set by founders Christopher Viehbacher and Robert Armstrong when they launched the in-licensing play with $600 million in 2015.

The deal gives Boston Pharmaceuticals Inc. worldwide development and commercialization rights to BOS-580, a preclinical FGF21 agonist, and comes seven months after the company appointed Novartis AG (NYSE:NVS; SIX:NOVN) vet Craig Basson as CMO. Basson was global head of translational medicine for cardiovascular and metabolic therapeutic areas at the Novartis Institutes for BioMedical Research. ...